Thrombocytopenia Management Market

SKU: DMPH4047 | Last Updated On: Sep 30 2021 | No. of Pages: 180 | Available Formats

> Global Thrombocytopenia Management Market Expected to reach a high CAGR By 2028: DataM Intelligence

Global Thrombocytopenia Management Market is segmented By Disease type (Idiopathic Thrombocytopenic, Thrombotic Thrombocytopenic, Drug-induced Thrombocytopenia), By End-user (Hospitals, Specialty Clinics, Ambulatory surgical centers), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2021-2028

 

Market Overview

The "Global Thrombocytopenia Management Market" is predicted to reach at a high CAGR during the forecast period (2021-2028) 

Thrombocytopenia is an autoimmune hematological bleeding disorder characterized by blood in urine, headaches, heavy menstrual period, spots on skin, and bruises. It can also be caused by cancer medications, including chemotherapy and drug-induced medicines, and radiation therapies.

Source: DataM Intelligence Analysis (2020)

Market Dynamics

Increasing prevalence rates for autoimmune hemolytic anemia is boosting the market growth.

Warm autoimmune hemolytic anemia (WAHA) is an autoimmune disorder characterized by the early destruction of healthy red blood cells (hemolysis). It occurs when one's immune system attacks healthy tissue. In WAHA and other types of autoimmune hemolytic anemia, red blood cells are tagged by antibodies and destroyed by other types of immune cells. It is the most common type of autoimmune hemolytic anemia.

According to the National Organization for Rare Disorders, WAHA affects approximately 1 to 3 per 100,000 people every year and can occur at any age. Usually, the red blood cells have a life span of approximately 120 days before the spleen destroys them. In patients with WAHA, the red blood cells are destroyed prematurely, and the increasing rate of new cells in the bone marrow can no longer pay for their loss. Additionally, the limited number of red blood cells may cause fatigue, weakness, a pale skin color (pallor), dizziness, palpitations, and shortness of breath (dyspnea). The treatment of WAHA includes corticosteroids and rituximab. Therefore, individuals who do not react to the usual treatment might require drugs that suppress the immune system, blood transfusions, or surgical spleen removal (splenectomy).

High cost of thrombocytopenia medications and treatment is likely to hamper the market growth.

The FDA has approved the anti–von Willebrand factor immunoglobulin fragment caplacizumab specifically indicated for treating adults with acquired thrombotic thrombocytopenic purpura (aTTP). But, with a list price of $270,000, the cost of the treatment outweighs its benefits.

In addition, treatment costs were calculated using U.S. list prices and facility costs. Researchers estimated treatment of a TTP episode would require four individual rituximab 375 mg/m2 doses, at the cost of $7,724 per dose; treatment with caplacizumab was $270,000 per episode. In addition, other associated costs accounted for in the model included the institution's costs for the number of TPE sessions ($6,000/TPE session), intensive care unit length of stay ($1,043/day), and total hospital length of stay ($490/day).

Market Industry Analysis

PESTAnalysis:

 

COVID-19 Impact Analysis

COVID-19 pandemic has moderately impacted the healthcare industry. Patients with COVID-19 pneumonia exhibit coagulation abnormalities, most commonly elevated levels of fibrinogen and D-dimer, often with mild thrombocytopenia and appear to have increased platelet consumption, together with a corresponding increase in platelet production. Disseminated intravascular coagulopathy (DIC) and severe bleeding events are uncommon in COVID-19 patients. Moreover, the pandemic is interrupting the medical supply chain, and many companies will vary to other geographic regions in the future to ensure that products remain available and protect their supply chain. However, the situation is expected to improve gradually in the forecast period.

Segment Analysis

Idiopathic Thrombocytopenic segment is expected to hold the largest market share in this market segment.

The idiopathic thrombocytopenic segment is held the largest market share in 2020. The segment growth is benefited due to the increasing prevalence of idiopathic thrombocytopenic purpura. For instance, according to the Mayoclinic,  idiopathic thrombocytopenic purpura is a disorder that can lead to excessive bruising and bleeding. The bleeding results from especially low levels of platelets — the cells that help blood clot. Children may develop ITP after a viral infection and usually recover fully without treatment. In adults, the disorder is often long-term. For instance, according to the National Organization for Rare Disorders, The incidence of ITP  and is more common over the age of 60 and increases with age. Among adults (age 30-60) diagnosed with chronic ITP, there are 2.6 cases amongst women for every case involving a male.

Moreover, in older adults, about the same number of men and women are diagnosed with ITP, whereas among children diagnosed with acute ITP, the male to female ratio is almost equal, with 52% male to 48% female. About 40% of all patients diagnosed with one or another form of ITP are children younger than ten years. Therefore, among children, the incidence is greatest between 2 and 4 years of age. However, ITP can occur at any age from 3 months to over 100 years of age.

Source: DataM Intelligence Analysis (2020)

Geographical Analysis

North America region holds the largest market share in the global thrombocytopenia management market

North America dominated the market in 2020, owing to the rising thrombocytopenia cases, favorable government initiatives and high research funding in the region is expected to boost the market in the forecast period. For instance, according to the Annals of Blood, published on March 2021, Immune thrombocytopenia (ITP) is a rare heterogeneous autoimmune bleeding disorder that makes a lower than normal circulating platelet count caused by impaired platelet production and accelerated platelet destruction.

Patients with ITP face a set of challenges. The multifaceted burden of living with ITP impacts patients and their families' overall health-related quality of life (HRQoL). Moreover, ITP leads to fatigue, challenges with daily activities, reduced physical functioning, anxiety, and depression. Aside from the constant risk for serious bleeding, patients experience physical and emotional consequences living with their disease daily. Additionally, ITP is primarily chronic in adults, with a higher prevalence in women than in men. The prevalence of ITP is 20.3 per 100,000 persons in the United States of America (USA). Thus, the North American region is expected to hold the largest market share in the forecast period from the above statements. 

Source: DataM Intelligence Analysis (2020)

Competitive Landscape

The thrombocytopenia management market is highly competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Amgen Inc., Amarillo Biosciences, Baxalta, Bayer, BioLineRx, Boehringer Ingelheim, Bolder Biotechnology, Bristol-Myers Squibb, Cellerant Therapeutics, Eisai and Genosco. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the thrombocytopenia management market globally.

Thrombocytopenia Management Market Key Companies to Watch

Amgen Inc.:

Overview:

Amgen Inc. (Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company focused on molecular biology and biochemistry. The company focuses on therapeutic areas: cardiovascular disease, oncology, bone health, neuroscience, nephrology and inflammation. Moreover, the company has a presence in around 100 countries and regions worldwide. In 2018, the company's largest selling product lines were Neulasta, an immunostimulator used to prevent infections in cancer chemotherapy patients and Enbrel, a tumor necrosis factor blocker used to treat rheumatoid arthritis autoimmune diseases.

Product Portfolio:

Amgen Inc. has continuously set new standards for manufacturing products, including Nplate (romiplostim).

Why Purchase the Report?

  • Visualize the composition of the thrombocytopenia management market segmentation by disease type, end user and region highlighting the key commercial assets and players.
  • Identify commercial opportunities in thrombocytopenia management market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of thrombocytopenia management market- level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global thrombocytopenia management market report would provide an access to an approx. 50 market data table, 41 figures and 180pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Market Segmentation

Global Thrombocytopenia Management Market – By Disease type

  • Idiopathic Thrombocytopenic
  • Thrombotic Thrombocytopenic
  • Drug-induced Thrombocytopenia

Global Thrombocytopenia Management Market – By End user

  • Hospitals
  • Specialty Clinics
  • Ambulatory surgical centers

Global Thrombocytopenia Management Market - By Region

  • North America
  • South America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Table of Contents

  1. Global Thrombocytopenia Management Market Methodology and Scope

    1. Research Methodology
    2. Research Objective and Scope of the Report
  2. Global Thrombocytopenia Management Market – Market Definition and Overview

  3. Global Thrombocytopenia Management Market – Executive Summary

    1. Market Snippet by Disease type
    2. Market Snippet by End user
    3. Market Snippet by Region
  4. Global Thrombocytopenia Management Market – Market Dynamics

    1. Market Impacting Factors
      1. Drivers
        1. Increase in prevalence rates for autoimmune hemolytic anemia
        2. Growing awareness and disposable income of thrombocytopenia management
      2. Restraints:
        1. High cost of thrombocytopenia medications and treatment is expected to hamper the market growth.
      3. Opportunity
      4. Impact Analysis
  5. Global Thrombocytopenia Management Market – Industry Analysis

    1. Porter's Five Forces Analysis
    2. Epidemiology Analysis
    3. Supply Chain Analysis
    4. Pricing Analysis
    5. Regulatory Analysis
    6. Reimbursement Analysis
    7. Unmet Needs
  6. Global Thrombocytopenia Management Market – COVID-19 Analysis

    1. Analysis of Covid-19 on the Market
      1. Before COVID-19 Market Scenario
      2. Present COVID-19 Market Scenario
      3. After COVID-19 or Future Scenario
    2. Pricing Dynamics Amid Covid-19
    3. Demand-Supply Spectrum
    4. Government Initiatives Related to the Market During Pandemic
    5. Manufacturers Strategic Initiatives
    6. Conclusion 
  7. Global Thrombocytopenia Management Market – By Disease type

    1. Introduction
      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease type
      2. Market Attractiveness Index, By Disease type Segment
    2. Idiopathic Thrombocytopenic*
      1. Introduction
      2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
    3. Thrombotic Thrombocytopenic
    4. Drug-induced Thrombocytopenia
  8. Global Thrombocytopenia Management Market – By End user

    1. Introduction
      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
      2. Market Attractiveness Index, By End user Segment
    2. Hospitals*
      1. Introduction
      2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
    3. Specialty Clinics
    4. Ambulatory surgical centers
  9. Global Thrombocytopenia Management Market – By Region

    1. Introduction
      1. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
      2. Market Attractiveness Index, By Region
    2. North America
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease type
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. U.S.
        2. Canada
        3. Mexico
    3. Europe
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease type
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. Germany
        2. U.K.
        3. France
        4. Italy
        5. Spain
        6. Rest of Europe
    4. South America
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease type
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. Brazil
        2. Argentina
        3. Rest of South America
    5. Asia Pacific
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease type
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. China
        2. India
        3. Japan
        4. Australia
        5. Rest of Asia Pacific
    6. Middle East and Africa
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease type
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
  10. Global Thrombocytopenia Management Market – Competitive Landscape

    1. Key Developments and Strategies
    2. Company Share Analysis
    3. Product Benchmarking
    4. List of Key Companies to Watch
    5. List of Company with disruptive technology
    6. List of Start Up Companies
  11. Global Thrombocytopenia Management Market- Company Profiles

    1. Amgen Inc.*
      1. Company Overview
      2. Product Portfolio and Description
      3. Key Highlights
      4. Financial Overview
    2. Amarillo Biosciences
    3. Baxalta
    4. Bayer
    5. BioLineRx
    6. Boehringer Ingelheim
    7. Bolder Biotechnology
    8. Bristol-Myers Squibb
    9. Cellerant Therapeutics
    10. Eisai
    11. Genosco(*LIST NOT EXHAUSTIVE)
  12. Global Thrombocytopenia Management Market – DataM

    1. Appendix
    2. About Us
    3. Contact Us

List of Tables & Figures

List of Tables

Table1   Global Thrombocytopenia Management Market Value, By Disease type, 2020, 2024 & 2028 ($ Million)

Table2 Global Thrombocytopenia Management Market Value, By End user, 2020, 2024 & 2028 ($ Million)

Table3 Global Thrombocytopenia Management Market Value, By Region, 2020, 2024 & 2028 ($ Million)

Table4 Global Thrombocytopenia Management Market Value, By Disease type, 2020, 2024 & 2028 ($ Million)

Table5 Global Thrombocytopenia Management Market Value, By Disease type, 2019-2028 ($ Million)

Table6 Global Thrombocytopenia Management Market Value, By End user, 2020, 2024 & 2028 ($ Million)

Table7 Global Thrombocytopenia Management Market Value, By End user, 2019-2028 ($ Million)

Table8 Global Thrombocytopenia Management Market Value, By Region, 2020, 2024 & 2028 ($ Million)

Table9 Global Thrombocytopenia Management Market Value, By Region, 2019-2028 ($ Million)

Table10 North America Thrombocytopenia Management Market Value, By Disease type, 2019-2028 ($ Million)

Table11  North America Thrombocytopenia Management Market Value, By End user, 2019-2028 ($ Million)

Table12 North America Thrombocytopenia Management Market Value, By Country, 2019-2028 ($ Million)

Table13 South America Thrombocytopenia Management Market Value, By Disease type, 2019-2028 ($ Million)

Table14 South America Thrombocytopenia Management Market Value, By End user, 2019-2028 ($ Million)

Table15 South America Thrombocytopenia Management Market Value, By Country, 2019-2028 ($ Million)

Table16 Europe Thrombocytopenia Management Market Value, By Disease type, 2019-2028 ($ Million)

Table17 Europe Thrombocytopenia Management Market Value, By End user, 2019-2028 ($ Million)

Table18 Europe Thrombocytopenia Management Market Value, By Country, 2019-2028 ($ Million)

Table19 Asia-Pacific Thrombocytopenia Management Market Value, By Disease type, 2019-2028 ($ Million)

Table20 Asia-Pacific Thrombocytopenia Management Market Value, By End user, 2019-2028 ($ Million)

Table21 Asia-Pacific Thrombocytopenia Management Market Value, By Country, 2019-2028 ($ Million)

Table22 Middle East & Africa Thrombocytopenia Management Market Value, By Disease type, 2019-2028 ($ Million)

Table23 Middle East & Africa Thrombocytopenia Management Market Value, By End user, 2019-2028 ($ Million)

Table24 Baxalta: Overview

Table25 Baxalta: Product Portfolio

Table26 Baxalta: Key Developments

Table27 Bayer: Overview

Table28 Bayer: Product Portfolio

Table29 Bayer: Key Developments

Table30 BioLineRx: Overview

Table31 BioLineRx: Product Portfolio

Table32 BioLineRx: Key Developments

Table33 Boehringer Ingelheim: Overview

Table34 Boehringer Ingelheim: Product Portfolio

Table35 Boehringer Ingelheim: Key Developments

Table36 Bolder Biotechnology: Overview

Table37 Bolder Biotechnology: Product Portfolio

Table38 Bolder Biotechnology: Key Developments

Table39 Bristol-Myers Squibb: Overview

Table40 Bristol-Myers Squibb: Product Portfolio

Table41 Bristol-Myers Squibb: Key Developments

Table42 Cellerant Therapeutics: Overview

Table43 Cellerant Therapeutics: Product Portfolio

Table44 Cellerant Therapeutics: Key Developments

Table45 Eisai: Overview

Table46 Eisai: Product Portfolio

Table47 Eisai: Key Developments

Table48 Genosco: Overview

Table49 Genosco: Product Portfolio

Table50 Genosco: Key Developments

List of Figures

Figure1  Global Thrombocytopenia Management Market Share, By Disease type, 2020 & 2028 (%)

Figure2 Global Thrombocytopenia Management Market Share, By End user, 2020 & 2028 (%)

Figure3  Global Thrombocytopenia Management Market Share, By Region, 2020 & 2028 (%)

Figure4 Global Thrombocytopenia Management Market Value, 2019-2028 ($ Million)

Figure5 Global Thrombocytopenia Management Market Y-o-Y Growth, By Disease type, 2020-2028 (%)

Figure6 Idiopathic Thrombocytopenic: Global Thrombocytopenia Management Market Value, 2019-2028 ($ Million)

Figure7 Thrombotic Thrombocytopenic: Global Thrombocytopenia Management Market Value, 2019-2028 ($ Million)

Figure8 Drug-induced Thrombocytopenia: Global Thrombocytopenia Management Market Value, 2019-2028 ($ Million)

Figure9 Global Thrombocytopenia Management Market Y-o-Y Growth, By End user, 2020-2028 (%)

Figure10 Hospitals: Global Thrombocytopenia Management Market Value, 2019-2028 ($ Million)

Figure11 Speciality Clinics: Global Thrombocytopenia Management Market Value, 2019-2028 ($ Million)

Figure12 Ambulatory Surgical Centres: Global Thrombocytopenia Management Market Value, 2019-2028 ($ Million)

Figure13 Global Thrombocytopenia Management Market Y-o-Y Growth, By Region, 2020-2028 (%)

Figure14 North America Thrombocytopenia Management Market Value, 2019-2028 ($ Million)

Figure15 North America Thrombocytopenia Management Market Share, By Disease type, 2020 & 2028 (%)

Figure16 North America Thrombocytopenia Management Market Share, By End user, 2020 & 2028 (%)

Figure17 North America Thrombocytopenia Management Market Share, By Country, 2020 & 2028 (%)

Figure18 South America Thrombocytopenia Management Market Value, 2019-2028 ($ Million)

Figure19 South America Thrombocytopenia Management Market Share, By Disease type, 2020 & 2028 (%)

Figure20 South America Thrombocytopenia Management Market Share, By End user, 2020 & 2028 (%)

Figure21 South America Thrombocytopenia Management Market Share, By Country, 2020 & 2028 (%)

Figure22 Europe Thrombocytopenia Management Market Value, 2019-2028 ($ Million)

Figure23 Europe Thrombocytopenia Management Market Share, By Disease type, 2020 & 2028 (%)

Figure24 Europe Thrombocytopenia Management Market Share, By End user, 2020 & 2028 (%)

Figure25 Europe Thrombocytopenia Management Market Share, By Country, 2020 & 2028 (%)

Figure26 Asia-Pacific Thrombocytopenia Management Market Value, 2019-2028 ($ Million)

Figure27 Asia-Pacific Thrombocytopenia Management Market Share, By Disease type, 2020 & 2028 (%)

Figure28 Asia-Pacific Thrombocytopenia Management Market Share, By End user, 2020 & 2028 (%)

Figure29 Asia-Pacific Thrombocytopenia Management Market Share, By Country, 2020 & 2028 (%)

Figure30 Middle East & Africa Thrombocytopenia Management Market Value, 2019-2028 ($ Million)

Figure31 Middle East & Africa Thrombocytopenia Management Market Share, By Disease type, 2020 & 2028 (%)

Figure32 Middle East & Africa Thrombocytopenia Management Market Share, By End user, 2020 & 2028 (%)

Figure33 Baxalta: Financials

Figure34 Bayer: Financials

Figure35 BioLineRx: Financials

Figure36 Boehringer Ingelheim: Financials

Figure37 Bolder Biotechnology: Financials

Figure38 Bristol-Myers Squibb: Financials

Figure39 Cellerant Therapeutics: Financials

Figure40 Eisai: Financials

Figure41 Genosco: Financials

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

20% Discount Applied*



Year-End Offer from
DataM Intelligence

Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!

linkedinpinterest